Kazakhstan Medical Device Authorized Representative: Duties and Post-market Obligations

1. Key takeaways

An authorized representative in Kazakhstan is not a submission agent. The center of gravity of its duties lies after the certificate is granted: the representative serves as the liaison node between the regulator, users and the manufacturer, takes on adverse event monitoring and post-market activities, and is named on the labels and instructions for use. The obligations of the representative are statutory; internal contractual arrangements do not release the representative toward the regulator. GRZAN recommends writing the responsibility list of the representative into the appointment agreement item by item, supported by verifiable work outputs such as logs, reports and response deadlines. The reasoning is simple: a duty that cannot be evidenced cannot be audited, and an unauditable duty is worthless in a dispute with either the regulator or the counterparty.

2. Legal basis

3. Expert insights

Insight one: the obligations of the representative are statutory, and contract terms operate only internally. The representative may agree on the internal division of work and fees with the manager of the certificate, but for the regulator the registered representative is the obligated party. This means a manufacturer cannot ring-fence risk through an arrangement under which the representative is merely nominal. Choosing a representative is choosing a compliance partner. This also explains why regulators take the registered identity of the representative seriously: it is the address at which enforcement action can actually be served and executed inside the jurisdiction.

Insight two: the duty list of the representative can be split into four categories. The first is liaison, answering inquiries from regulators, healthcare institutions and users. The second is monitoring, collecting, evaluating and reporting adverse events. The third is record keeping, maintaining logs and retaining documents. The fourth is cooperation, supporting inspections, market sampling and recall execution. Writing the four categories separately into the agreement makes later performance reviews straightforward. It also makes pricing transparent, because each category can be scoped and fee-rated on its own instead of hiding inside a single undifferentiated service charge.

Insight three: naming the representative on labels and instructions for use makes the duties public. The name of the representative appears on every item of material that circulates with the product, so users and regulators can contact it directly. This also means that weak capability on the side of the representative directly damages the market reputation of the manufacturer. Hospitals, procurement bodies and distributors routinely read the label contact as a signal of how seriously the manufacturer takes the market.

Insight four: the monitoring rules differ between the Union pathway and the national pathway, and so do the duties of the representative. Products registered under national rules fall under Order No. ҚР ДСМ-320/2020, while products registered under Union rules fall under Decision No. 174. Where a portfolio combines both pathways, the representative must be familiar with two sets of rules at the same time, which is a hidden requirement when selecting a representative. Report formats, reporting timelines and authority contact points differ between the two regimes, and a representative fluent in only one of them will create friction in exactly the months when reports are due.

Insight five: the duties of the representative and those of the manufacturer do not fully overlap. The manufacturer carries responsibility across the whole product life cycle, while the representative carries the in-country handover responsibilities. There is overlap but also division of work, so the agreement should define the deadlines and formats for information transfer, avoiding a situation in which each party assumes the other is acting. As a practical estimate, the agreement should fix both an escalation path and a fallback: if the representative cannot act within the agreed deadline, the manufacturer must know who steps in and on what authority.

4. Practical recommendations

1. Itemize the duties of the representative in the appointment agreement under the four categories of liaison, monitoring, record keeping and cooperation.
2. Attach verifiable work outputs to each category of duty: log templates, report formats and response deadlines.
3. When selecting a representative, assess whether it is familiar with both Order No. ҚР ДСМ-320/2020 and Decision No. 174.
4. Define the deadlines and formats for information transfer to prevent gaps in obligations.
5. Review the performance records of the representative on a regular basis, quarterly as a practical estimate.

5. Verification checklist

• □ The appointment agreement itemizes duties under the four categories of liaison, monitoring, record keeping and cooperation
• □ Each category of duty has verifiable work outputs attached, including logs, reports and deadlines
• □ The representative is familiar with Order No. ҚР ДСМ-320/2020 and Decision No. 174
• □ Deadlines and formats for information transfer are defined in the agreement
• □ A periodic review mechanism for the performance records of the representative is in place
• □ Representative information is correctly named on labels and instructions for use

Regulatory information verified as of October 29, 2026.

GRZAN provides registration support in Kazakhstan for medical device manufacturers, importers and authorized representatives, including post-market vigilance setup and representative performance management. Duty matrices and reporting templates are tailored to the four responsibility categories described above. For inquiries, contact info@grzanglobal.com.